Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

Rhea-AI Summary

Rafael Holdings (NYSE: RFL) secured an exclusive U.S. license from MIT for U.S. Patent No.12285440 covering the use of cyclodextrins as an API to treat ApoE4‑positive Alzheimer’s disease. The agreement strengthens Rafael’s IP around Trappsol® Cyclo™ and targets a patient subgroup estimated at 50–70% of AD cases. Preclinical data show improved CNS cholesterol transport, reduced tau pathology, and memory benefits in mice. Rafael also notes Transport NPC Phase 3 results due in calendar Q3 2026, highlighting near‑term clinical milestones.

Positive

• Exclusive license of U.S. Patent No.12285440 for cyclodextrin use in ApoE4 AD
• Targets 50–70% of AD patients carrying the ApoE4 variant
• Phase 3 catalyst with Transport NPC results due in calendar Q3 2026

Negative

• No clinical AD data for Trappsol Cyclo in ApoE4 patients yet
• Preclinical evidence only for reduced tau pathology and memory improvement in mice
• Outcome timing risk tied to Phase 3 Transport NPC results due Q3 2026

News Market Reaction – RFL

+1.56%

3 alerts

+1.56% Session close to close

+3.8% Peak Tracked

$71.75M Market Cap

0.7x Rel. Volume

In the Apr 22 session, RFL gained 1.56%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.8% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds an MIT patent license for ApoE4-positive Alzheimer’s Disease, broadening Rafa...

Analysis

This announcement adds an MIT patent license for ApoE4-positive Alzheimer’s Disease, broadening Rafael’s IP around Trappsol® Cyclo™ beyond Niemann-Pick Disease Type C1. The deal complements earlier disclosures about the pivotal Phase 3 Transport NPC trial, with topline data expected in Q3 2026. Investors may focus on how this Alzheimer’s opportunity fits with existing resources, prior R&D ramp-up, and the company’s ability to translate preclinical ApoE4 data into later-stage studies.

Key Figures

Patent number: U.S. Patent No. 12285440 ApoE4 prevalence: 50–70% Phase 3 results timing: Q3 2026

3 metrics

Patent number U.S. Patent No. 12285440 MIT patent licensed for ApoE4-positive Alzheimer’s

ApoE4 prevalence 50–70% Estimated share of Alzheimer’s patients with ApoE4 variant

Phase 3 results timing Q3 2026 Expected Transport NPC Phase 3 topline results

Historical Context

4 past events · Latest: Mar 16 (Neutral)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 16	Q2 2026 earnings	Neutral	+0.8%	Reported Q2 2026 loss, higher R&D and confirmed Phase 3 TransportNPC timeline.
Dec 11	Q1 2026 earnings	Neutral	-2.0%	Detailed Q1 loss, rising R&D and consolidation of Cyclo after acquisition.
Oct 29	FY 2025 results	Neutral	+0.8%	Reported FY 2025 loss, rights offering proceeds and ongoing TransportNPC review.
Oct 28	Board changes	Neutral	+0.0%	Announced passing of lead director and appointment of new board members and roles.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent earnings and governance headlines have produced relatively small price reactions, suggesting a history of muted responses to news.

Recent Company History

Over the past six months, Rafael’s key news has centered on fiscal 2025–2026 earnings and the Cyclo Therapeutics integration. Multiple releases on TransportNPC™ Phase 3 progress and higher R&D spending highlighted the pivot toward Trappsol® Cyclo™. Governance changes on Oct 28, 2025 brought a new director and committee reshuffle with no notable price move. Against this backdrop, the new MIT patent license further builds the Trappsol® Cyclo™ franchise beyond Niemann-Pick Disease Type C1.

Key Terms

active pharmaceutical ingredient, alzheimer's disease, apoe4, mechanism of action, +4 more

8 terms

active pharmaceutical ingredient technical

"around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment"

The active pharmaceutical ingredient (API) is the chemical or biological substance in a medicine that produces the intended therapeutic effect, separate from inactive ingredients like fillers, binders or coatings. Investors watch APIs closely because their source, patent status, manufacturing cost, quality controls and supply reliability drive a drug’s safety, regulatory approval, margin and commercial potential—like the engine in a car determining performance and value.

alzheimer's disease medical

"in patients with Alzheimer's Disease (AD) who carry an ApoE4 genetic mutation"

A progressive brain disorder that slowly erodes memory, thinking and the ability to carry out daily tasks as nerve cells are damaged and lost; symptoms typically worsen over years and can lead to severe impairment. Investors care because it drives a large, growing market for diagnostics, treatments and care services, but also carries high scientific, regulatory and commercial risk—similar to developing a complex new product that must pass difficult safety tests before it can reach patients.

apoe4 medical

"The ApoE4 gene variant is estimated to be present in 50-70% of patients"

APOE4 is a specific version of the APOE gene that increases the risk of developing Alzheimer’s disease and can influence how people respond to certain treatments. For investors, APOE4 matters because its prevalence in patient groups can shape clinical trial results, regulatory decisions and market size for therapies—like knowing a neighborhood’s weather pattern affects how many umbrellas a seller should stock.

mechanism of action medical

"The established mechanism of action (MOA) for Trappsol® Cyclo™ could have"

Mechanism of action describes how a drug, therapy, or medical product produces its effect in the body—the specific steps, targets, and biological processes it engages, like a key fitting into a lock to open a door. Investors care because a clear, well-understood mechanism reduces scientific uncertainty, supports regulatory approval and market confidence, and helps predict safety, effectiveness and additional uses, all of which influence a product’s commercial potential and a company’s valuation.

central nervous system medical

"improve cholesterol transport between central nervous system (CNS) cells"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

tau-pathology medical

"suggest Trappsol® Cyclo™ can improve delivery of cholesterol between CNS cells, reduce tau-pathology"

Tau-pathology is the buildup and abnormal clumping of tau protein inside brain cells that disrupts their shape and communication, contributing to cognitive decline in disorders such as Alzheimer’s. For investors, it matters because therapies or diagnostics that detect, slow, or clear these tau tangles can determine the commercial and regulatory fate of drugs and diagnostics—think of untangling a string of lights so a circuit works again, which affects market value and risk.

phase 3 medical

"“With Phase 3 results from Transport NPC due in calendar Q3, 2026, we’re excited"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

niemann-pick disease type c1 medical

"Phase 3 Transport NPC due in calendar Q3, 2026... disease areas. Our NPC1 phase 3 study"

A rare, inherited neurological disorder caused by mutations in the NPC1 gene that prevent cells from moving and disposing of cholesterol and other fats, causing them to build up like a clogged drain inside brain and other cells. Symptoms progress over time—often including movement problems, cognitive decline, and organ dysfunction—making it a severe unmet medical need and a focus for drug development, regulatory incentives, and potential investment in treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s Disease

NEWARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology (“MIT”) covering U.S. Patent No.12285440. This license covers the use of cyclodextrins in patients with Alzheimer's Disease (AD) who carry an ApoE4 genetic mutation, strengthening the company’s intellectual property portfolio around Trappsol^® Cyclo™ in this important AD patient population.

The ApoE4 gene variant is estimated to be present in 50-70% of patients with AD and is believed to be a key risk factor in the development early onset sporadic AD. Dysregulated cholesterol metabolism is believed to contribute to amyloid and tau pathology, especially in those patients with the ApoE4 gene variant, which has been shown to accelerate AD as it is the key lipids/cholesterol transporter in the brain.

The established mechanism of action (MOA) for Trappsol^® Cyclo™ could have a direct impact in ApoE4 positive patients as it has been shown to improve cholesterol transport between central nervous system (CNS) cells. Preclinical data suggest Trappsol^® Cyclo™ can improve delivery of cholesterol between CNS cells, reduce tau-pathology and improve learning/memory in mice.

“Securing this exclusive license from MIT represents a transformative milestone for our company and greater potential positive news for the millions of patients and their families affected by Alzheimer's disease. By combining the results of MIT's world-class foundational research with our clinical development expertise, we are well positioned to accelerate a potential breakthrough that addresses the underlying pathology of this devastating condition. This agreement underscores our commitment to pursuing the highest caliber of innovation to deliver life-changing therapies to patients in need," said Howard Jonas, CEO, Executive Chairman and Chairman of the Board of Rafael Holdings.

“With Phase 3 results from Transport NPC due in calendar Q3, 2026, we’re excited by Trappsol^® Cyclo™’s potential across multiple disease areas. Our NPC1 phase 3 study is the largest ever conducted in patients with NPC, yielding crucial clinical and safety data needed to advance the treatment paradigm for patients and families dealing with NPC " said Joshua Fine, COO of Rafael Holdings.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is Trappsol^® Cyclo™,which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company. Our lead candidate, Trappsol^® Cyclo™ is the subject of an ongoing pivotal Phase 3 clinical trial.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2025, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contact:
Barbara Ryan
Barbara.ryan@rafaelholdings.com
(203) 274-2825

FAQ

What does Rafael Holdings (RFL) licensing MIT patent No.12285440 mean for shareholders?

It grants Rafael an exclusive U.S. license to use cyclodextrins for ApoE4‑positive AD, strengthening IP position for Trappsol Cyclo. According to Rafael, this expands proprietary rights and could support development programs targeting a patient subgroup representing an estimated 50–70% of Alzheimer’s cases.

How might the MIT license affect Trappsol Cyclo’s development for ApoE4 Alzheimer’s (RFL)?

The license secures IP protection for Trappsol Cyclo in ApoE4 patients, potentially enabling focused trials and exclusivity. According to Rafael, combining MIT foundational research with the company’s development expertise aims to accelerate programs addressing cholesterol transport and tau pathology in this subgroup.

What evidence supports Trappsol Cyclo’s activity in ApoE4‑positive Alzheimer’s disease (RFL)?

Preclinical studies suggest Trappsol Cyclo improves CNS cholesterol transport, reduces tau pathology, and enhances learning/memory in mice. According to Rafael, these data form the mechanistic rationale but clinical efficacy in ApoE4 AD patients has not yet been demonstrated.

When are the next clinical milestones for Rafael Holdings (RFL) related to Trappsol Cyclo?

A key near‑term milestone is the Transport NPC Phase 3 results, expected in calendar Q3 2026. According to Rafael, those Phase 3 data represent a major clinical catalyst and may inform broader development across multiple disease areas.

Does the MIT agreement give Rafael exclusive rights in the U.S. for ApoE4 Alzheimer’s (RFL)?

Yes; the company says the agreement provides an exclusive U.S. license for the specified patent covering cyclodextrin use in ApoE4 AD. According to Rafael, exclusivity strengthens the company’s intellectual property around Trappsol Cyclo for this patient population.

What are the main risks for investors after Rafael’s (RFL) MIT licensing announcement?

Primary risks include the absence of human AD efficacy data and reliance on preclinical results and upcoming Phase 3 NPC data. According to Rafael, clinical validation in ApoE4 patients remains required and timing/outcomes of trials present execution risk for investors.